

January 2020

New specialty pharmacy medical injectable step therapy requirements

Effective for dates of service on and after March 1, 2020, the following medical injectable drugs and corresponding codes will be included in our medical step therapy precertification review process. Step therapy review will apply upon precertification initiation or renewal in addition to other current medical necessity review of all drugs noted below. Haegarda® and Takhzyro™ will be the preferred prophylactic agents over Cinryze®.

The *Clinical Criteria* below will be updated to include the required trial of the preferred drug:

<i>Clinical Criteria</i>	Preferred drug	Nonpreferred drug
ING-CC-0034	Haegarda (J0599)	Cinryze (J0598)
ING-CC-0034	Takhzyro (J3490, J3590, C9399)	Cinryze (J0598)

Clinical Criteria is made publicly available on our provider website. Visit the [Clinical Criteria website](#) to search for specific *Clinical Criteria*.

For questions or additional information, use this [email](#).

* This link leads to a third-party site. That organization is solely responsible for the contents and privacy policies on its site.

www.HealthyBlueSC.com

BlueChoice HealthPlan is an independent licensee of the Blue Cross and Blue Shield Association. BlueChoice HealthPlan has contracted with Amerigroup Partnership Plan, LLC, an independent company, for services to support administration of Healthy Connections. To report fraud, call our confidential Fraud Hotline at 877-725-2702. You may also call the South Carolina Department of Health and Human Services Fraud Hotline at 888-364-3224 or email fraudres@scdhhs.gov.
BSC-NL-0174-19 January 2020